Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Core Insights - Invivyd, Inc. has established the SPEAR Study Group to investigate the effects of monoclonal antibody therapy on Long COVID and Post-Vaccination Syndrome, focusing on the role of persistent SARS-CoV-2 spike protein [1][2][4] Group 1: SPEAR Study Group Formation - The SPEAR Study Group aims to conduct clinical trials evaluating broadly neutralizing anti-SARS-CoV-2 spike protein monoclonal antibody therapy for patients suffering from Long COVID and PVS [1][2] - The initiative was prompted by increasing anecdotal evidence suggesting symptom relief in Long COVID patients following treatment with PEMGARDA (pemivibart), a monoclonal antibody authorized for COVID-19 prevention in immunocompromised individuals [2][5] - The group includes leading researchers in the field, such as Dr. Michael Peluso, Dr. Amy Proal, and Dr. David Putrino, who will collaborate on the design and execution of clinical trials [3][6] Group 2: Clinical Research and Objectives - The SPEAR Study Group plans to initiate multi-center translational clinical research on Long COVID and PVS, utilizing next-generation monoclonal antibody candidates like VYD2311 [3][5] - Initial efforts will focus on rigorous assessments of monoclonal antibody safety, translational biology, and exploratory efficacy in patients with persistent viral reservoirs or circulating spike protein [5][7] - The research aims to explore the underlying biology of Long COVID and establish efficacy endpoints that could support future registrational studies [2][4] Group 3: Monoclonal Antibody Overview - PEMGARDA is a half-life extended investigational monoclonal antibody that has shown in vitro neutralizing activity against major SARS-CoV-2 variants [8][9] - The antibody targets the spike protein receptor binding domain, inhibiting virus attachment to human cells [8] - VYD2311 is a novel monoclonal antibody candidate developed to address the urgent need for new COVID-19 prophylactic and therapeutic options, leveraging Invivyd's proprietary technology platform [15][16]